Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -19.35% is 60% above its 5-year average of -47.86%, near the high end of its 5-year range (-77.61%–-19.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 49.13% above its 12-month average of -38.04%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -19.35%.
RETURN ON EQUITY (ROE)
-19.35%
RETURN ON EQUITY (ROE) AVG TTM
-38.04%
RETURN ON EQUITY (ROE) AVG 3Y
-51.89%
RETURN ON EQUITY (ROE) AVG 5Y
-47.86%
RETURN ON EQUITY (ROE) AVG 10Y
-52.30%
RETURN ON EQUITY (ROE) AVG 15Y
-47.88%
RETURN ON EQUITY (ROE) AVG 20Y
-47.62%
CURRENT VS TTM AVG
+49.13%
CURRENT VS 3Y AVG
+62.71%
CURRENT VS 5Y AVG
+59.57%
CURRENT VS 10Y AVG
+63.00%
CURRENT VS 15Y AVG
+59.58%
CURRENT VS 20Y AVG
+59.37%
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 341 covered companies
CURRENT VS SECTOR MEDIAN
+33.62%
vs the sector median at left
Altimmune, Inc.
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-38.04%
3Y Avg
-51.89%
5Y Avg
-47.86%
Market Cap
$517.79M
Return on Equity (ROE)
-99.83%
TTM Avg
118.83%
3Y Avg
8.21%
5Y Avg
-14.12%
Market Cap
$517.73M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$491.93M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
Market Cap
$491.55M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$547.86M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$487.30M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$481.33M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$478.54M
Return on Equity (ROE)
-24.02%
TTM Avg
-22.16%
3Y Avg
-34.88%
5Y Avg
-37.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Altimmune, Inc. (ALT) | $519.25M | -19.35% | -38.04% | -51.89% | -47.86% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -99.83% | 118.83% | 8.21% | -14.12% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -37.94% | -63.13% | -60.30% | -47.34% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | -344.79% | -198.42% | -104.57% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -6.60% | -10.82% | -11.36% | -7.59% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.44% | -17.98% | 71.24% | -6.51% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | -8.21% | -32.76% | -79.80% | -71.61% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.65% | -27.02% | -39.92% | -33.78% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -24.02% | -22.16% | -34.88% | -37.32% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
ROE
-19.4%
ROA
-17.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -19.35% |
| 2026-03-31 | -32.07% |
| 2025-12-31 | -39.17% |
| 2025-09-30 | -45.21% |
| 2025-06-30 | -54.38% |
| 2025-03-31 | -63.48% |
| 2024-12-31 | -76.97% |
| 2024-09-30 | -77.61% |
| 2024-06-30 | -66.44% |
| 2024-03-31 | -53.64% |
| 2023-12-31 | -45.57% |
| 2023-09-30 | -52.17% |
| 2023-06-30 | -48.48% |
| 2023-03-31 | -50.89% |
| 2022-12-31 | -45.72% |
| 2022-09-30 | -42.40% |
| 2022-06-30 | -49.83% |
| 2022-03-31 | -54.99% |
| 2021-12-31 | -48.76% |
| 2021-09-30 | -40.06% |
| 2021-06-30 | -28.22% |
| 2021-03-31 | -24.36% |
| 2020-12-31 | -21.71% |
| 2020-09-30 | -21.29% |
| 2020-06-30 | -44.88% |
| 2020-03-31 | -53.25% |
| 2019-12-31 | -45.08% |
| 2019-09-30 | -82.88% |
| 2019-06-30 | -57.52% |
| 2019-03-31 | -64.22% |
| 2018-12-31 | -81.08% |
| 2018-09-30 | -59.21% |
| 2018-06-30 | -142.55% |
| 2018-03-31 | -96.83% |
| 2017-12-31 | -90.48% |
| 2017-09-30 | 87.22% |
| 2017-06-30 | 239.19% |
| 2016-12-31 | 996.21% |
| 2016-09-30 | 84.19% |
| 2016-06-30 | 17.54% |
| 2016-03-31 | -39.23% |
| 2015-12-31 | -20.67% |
| 2015-09-30 | -27.34% |
| 2015-06-30 | -44.37% |
| 2015-03-31 | -31.13% |
| 2014-12-31 | -54.48% |
| 2014-09-30 | -64.90% |
| 2014-06-30 | -101.87% |
| 2014-03-31 | -142.52% |
| 2013-12-31 | -159.74% |
| 2013-09-30 | -75.42% |
| 2013-06-30 | -36.55% |
| 2013-03-31 | -43.77% |
| 2012-12-31 | -42.15% |
| 2012-09-30 | -23.12% |
| 2012-06-30 | -20.09% |
| 2012-03-31 | -31.96% |
| 2011-12-31 | -23.96% |
| 2011-09-30 | -142.60% |
| 2011-06-30 | -177.83% |
| 2011-03-31 | -267.46% |
| 2010-12-31 | -285.40% |
| 2009-09-30 | -490.39% |
| 2009-06-30 | -214.78% |
| 2009-03-31 | -225.72% |
| 2008-12-31 | -192.03% |
| 2008-09-30 | -325.15% |
| 2008-06-30 | -219.27% |
| 2008-03-31 | -29.47% |
| 2007-12-31 | -13.03% |
| 2007-09-30 | 0.09% |
| 2007-03-31 | 2.01% |
| 2006-12-31 | 1.78% |
| 2006-09-30 | 1.62% |
| 2006-06-30 | 1.36% |
